CIRSE: What distinguishes this latest iteration of the PAE course from the previous couses that we have offered?
Aldin: In this course, we will focus on the latest evidence for prostatic artery embolization (PAE), including its recent inclusion in the American Urological Association guidelines as of September 2023. We will present recorded cases that demonstrate how to perform PAE in various clinical and anatomical scenarios, providing step-by-step guidance on performing radial PAE, a technique particularly useful for patients with tortuous iliac anatomy. Additionally, we will showcase a case with practical tips on using glue embolization, which has not been covered in previous courses.
Our fantastic collection of cases for simulator training will be supervised by our experienced faculty. The course incorporates the latest updates on the evidence for PAE and addresses all challenging PAE cases, ensuring participants are equipped with the most current knowledge and skills
CIRSE: How will this course enhance attendees’ practice and patient care outcomes?
Aldin: Participants will leave the course with practical knowledge on patient triage, selection, and the technical aspects of PAE, including considerations for repeat procedures, which is a new and big thing now. They will learn when to repeat PAE and when to refer patients to surgeons. The course will also cover new embolic agents, such as glue, and strategies to address urologists’ current arguments against prostatic artery embolization.
CIRSE: What are some of these arguments against PAE?
Aldin: One of the arguments against PAE is the lack of long-term data. We are currently in the process of collecting this data, and expect to have more comprehensive long-term results within the next three to five years. Another concern is the recurrence rate of symptoms after PAE; about 20% of patients may experience symptom recurrence within five years. However, our argument is that these patients have the option to undergo the procedure again or choose surgical alternatives. It’s important to note that similar recurrence rates are observed with TURP, where patients may require a repeat procedure five to ten years after the initial treatment.
CIRSE: What are you most looking forward to for the course?
Aldin: I look forward to meeting all the participants and faculty! The support from ESIR has been very helpful. The course is scheduled for July, which is a wonderful time to visit the UK.
Join Dr. Aldin and other leading experts at the ESIR course on prostatic artery embolization July 4-5 at the Princess Alexandra Hospital in Essex, UK! Click on the links below to register, browse the programme, or explore all upcoming ESIR courses.